

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 68776

Title: Anti-Programmed Death 1 antibody in the treatment of coexistent M. fortuitum and lung cancer: A case report and literature review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05658248

Position: Peer Reviewer

Academic degree: FRACP, MBBS

Professional title: Academic Research, Assistant Lecturer, Consultant Physician-Scientist, Doctor

Reviewer's Country/Territory: Australia

Author's Country/Territory: China

Manuscript submission date: 2021-06-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-04 11:08

Reviewer performed review: 2021-07-25 02:00

Review time: 20 Days and 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection

Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Please review the following article and incorporate into the paper: Anastasopoulou, A., Ziogas, D.C., Samarkos, M. et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. *J. immunotherapy cancer* 7, 239 (2019). <https://doi.org/10.1186/s40425-019-0717-7>

Need to clarify if TB reactivation (M. fortuitum infection) has been in the presence of anti-TB treatment. If so, how can we explain the appearance of M. fortuitum reactivation within 14 days of combined anti-TB and anti-PD1 therapies. Why the infection resolved while continuing the same therapies? Could this new lesion represent a form of pseudoprogression? I believe that M. fortuitum reactivation (lesion in the subpleural mass in the anterior segment of the left upper lobe) is due to anti-PD1 therapy rather than anti-TB therapy. See review article above. Could that be confirmed with expertise?

Need to highlight the importance of multidisciplinary meetings involving TB experts when treating complicated patients.

Minor changes: Please mention the dates of scans in the text. Please mention what assay used to test PD-L1. I cannot find a reason/rational for showing figure 1(The expression of PD-L1).